[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_6685 

# __Repurposing existing drugs without sufficient evidence for effectiveness against covid-19__

## Articles mentionning the risk

* [Chamola_comprehensive_2020](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_430.md)

## Mitigations of this risk

* [Conducting comprehensive studies and trials to validate the effectiveness of repurposed drugs](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_8559.md)

## Name of the risk

Increased risk of using drugs that may not be effective against COVID-19

## People affected by this risk

* [Healthcare providers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_31.md)
* [Patients](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_121.md)
* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Stakeholders who can mitigate this risk

* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_413.md)
* [Regulatory authorities](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)
* [Research institutions](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_1293.md)

## Technologies linked to the risk

* [Clinical trial platforms](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_8133.md)
* [Drug validation technologies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_8134.md)

## This Risk belongs to this RiskGroup

* [Technological risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_8.md)

